ACUTE RESPIRATORY INFECTIONS IN CHILDREN WITH ALLERGY: PROBLEMS WITH ANTIBACTERIAL AGENT CHOICE
https://doi.org/10.15690/vsp.v12i1.569
Abstract
Acute respiratory infections represent the most common disease among children. In addition to that, children with predisposition to allergy have respiratory infection more often and their clinical course is more severe than in non-allergic children at the same age. Respiratory infections in patients with predisposition to allergy often have complicated or chronic course without appropriate treatment. Timely and appropriate therapy of such conditions contributes to faster recovery and prevents complications. Modern macrolide antibiotics are the drugs of choice in treatment of acute respiratory mixed (viral and bacterial) or bacterial infections in children with allergy. One of the most commonly administered antibacterial agents in allergology practice is azithromycin. It is due to its high efficacy against out-of-hospital causative agents of respiratory infections, including atypical, significantly higher and more stable tissue concentrations, prolonged semiejection period and possibility of one-time intake per day, as well as low risk of allergic reactions. Appropriateness of azithromycin usage in allergic reactions is also caused by its non-antibacterial properties: anti-inflammatory and immunomodulatory activity.
About the Author
O. V. Zaitseva
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
References
1. Salvo F., De Sarro A., Caputi A. P., Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Exp. Opin. Drug. Saf. 2009; 8 (1): 111–118.
2. Demoly P., Benahmed S., Valembois M. et al. Allergy to macro lide antibiotics. Review of the literature. Presse Med. 2000; 29 (6): 321–326.
3. Lee C. E., Zembower T. R., Fotis M. A. et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch. Intern. Med. 2000; 160 (18): 2819–2822.
4. Kozlov R. S., Krechikova O. I. et al. Dynamics of S. Pneumonia resistance to antibiotics in Russia during 1999–2009: results of multicenter prospective study PeGAS. Clinical microbiology and antimicrobial chemotherapy. 2010; 12 (4): 329–341.
5. Reshedko G. K., Kozlov R. S. The state of resistance to antiinfection drugs in Russia. In a book: Practical guideline on antiinfection chemotherapy. Edited by L. S. Strachunskiy, Yu. B. Belousov, R. S. Kozlov. Moscow. 2007. Pp. 32–47.
6. Strachunskiy L. S., Kozlov S. N. Macrolides in modern clinical practice. Smolensk: Rusich. 1998. 304 pp.
7. Bauernfeind A. In vitro activity of diritrimycin in comparison with other new and established macrolides. J. Antimicrob. Chemother. 1993; 31 (Suppl.): 39–49.
8. Foulds G., Shepard R., Johnson R. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 1990; 25 (Suppl. A): 73–82.
9. Practical guideline on anti-infection chemotherapy. Edited by Strachunskiy L. S., Belousov Yu. B., Kozlov S. N. Moscow: Borges. 2002. 379 pp.
10. Handbook on antimicrobial therapy. Smolensk. 2006.
11. Strachunskiy L. S., Kozlov S. N. Macrolides in modern clinical practice. Smolensk. 1998.
12. Veselov A. V., Kozlov R. S. Clinical microbiology and antimicrobial chemotherapy. 2006; 8 (1): 18.
13. Treadway G., Pontani D. J. Antimicrob. Chemother. 1996; 7 (Suppl. C): 143.
14. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. Epub. 2011.
15. Antibiotics and the Lung. Eur. Respir. Monograph. M. Cazzola, F. Blasi, S. Ewig (eds.). 2004; 9: 28.
16. Labro M. T. Antibiotics as anti-inflammatory drugs. Curr. Opin. Investig. Drugs. 2002; 3: 61–68.
17. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004; 125 (Suppl.): 41–51.
18. Equi A., Balfour-Lynn I. M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet. 2002; 360: 978–984.
19. Amsden G. W. Anti-inflammatory effects of macrolides — an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. J. Antimicrob. Chemother. 2005; 55 (1): 10–21.
20. Harris J. A. et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. 1998; 17 (10): 865.
21. Wubbel L. et al. Etiology and treatment of community-acquired pneu monia in ambulatory children. Pediatr. Infect. Dis. J. 1999; 18 (2): 98.
22. Barsic B. Abstracts of the 20th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases). Vienna, Austria. April 10–13. 2010. 174 p.
Review
For citations:
Zaitseva O.V. ACUTE RESPIRATORY INFECTIONS IN CHILDREN WITH ALLERGY: PROBLEMS WITH ANTIBACTERIAL AGENT CHOICE. Current Pediatrics. 2013;12(1):131-135. (In Russ.) https://doi.org/10.15690/vsp.v12i1.569
Views:
998
Email this article 
